Team
Stanley D. Rose, Ph.D.
President and Managing Partner Stan Rose is a Ph.D. biologist, life sciences executive, and serial entrepreneur. He has spent over three decades working with leading scientists and clinicians to create substantial commercial value from inventions related to DNA and genome analysis. He has raised more than $100 million in startup funding and led businesses to create more than $1 billion in market value for shareholders, commercializing life science products impacting the lives of millions.
Dr. Rose currently serves on the Board of Xeno Biosciences, a drug development company dedicated to finding safe and effective treatments for obesity and metabolic diseases. Dr. Rose is a Director of SerumDPT Bioscience, who have created the first device enabling real-time isolation of plasma or serum from drawn blood. He is a co-founding director of a stealth startup in the oncology therapeutics space. He also serves as a Senior Fellow with the Council on Strategic Risks, participating in The Alliance to End Biological Threats.
Dr. Rose was co-founder, President and CEO of Transplant Genomics Inc. (acquired by Eurofins in 2019), whose TruGraf® blood gene expression tests enable doctors to rule out silent rejection in kidney transplant recipients.
Dr. Rose was a Director of Cellular Dynamics International (NASDAQ: ICEL), a leader in pluripotent stem cell technology for drug discovery and cell therapy (acquired by FujiFilm in 2015), and Chair of the Market Advisory Board for Cyvek, a protein immunoassay and immuno-diagnostics company (acquired by BioTechne in 2014).
Highlights from earlier in his career include serving as CEO of NimbleGen Systems, a genomics tools company, from 2003 through its acquisition by Roche in 2007; co-founding and growing Genetic MicroSystems, a microarray instrumentation company that was acquired by Affymetrix in 2000; and directing the PCR business for Perkin-Elmer and Applied Biosystems during its most dynamic growth phase in the 1990s.
Dr. Rose received his B.A. from Cornell University and his Ph.D. from the Massachusetts Institute of Technology.
